BIOMAT Database Logo BIOMAT Database Logo

[Control of hyperinsulinemia in essential hypertension using the angiotensin-converting enzyme inhibitor, lisinopril]. 1993

V Umnerová, and M Jarolím, and A Jindra, and M Jáchymová, and J Peleska, and J Savlíková, and P Stolba, and K Horký
II. interní klinika a kardiologická laborator 1. lékarské fakulty Univerzity Karlovy, Praha, Ceská republika.

Hyperinsulinaemia and insulin resistance are associated with essential hypertension irrespective of obesity and non-insulin-dependent diabetes mellitus. One of the mechanisms whereby hyperinsulinaemia may play a role in the increase in blood pressure, is an increased activity of the sympathetic nervous system. The authors studied the incidence of hyperinsulinaemia, and the possibility of modulating it by 12-week administration of the ACE inhibitor (ACEI) lisinopril (Prinivil by MSD) at a dose of 20-40 mg/day. Compared with normotensive subjects, hypertensives showed a degree of hyperinsulinaemia and insulin resistance (higher blood glucose at higher immunoreactive insulin and C-peptide concentrations, and a higher IRI/blood glucose ratio) as well as manifestations of enhanced sympathetic activity (higher adrenaline levels). Lisinopril had a favourable effect not only on blood pressure but, also, on hyperinsulinaemia and adrenaline levels. It can be reasonably concluded that therapy with ACEI, in addition to its antihypertensive effect, may also favourably modulate some pathogenic and metabolic factors in essential hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D002395 Catecholamines A general class of ortho-dihydroxyphenylalkylamines derived from TYROSINE. Catecholamine,Sympathin,Sympathins
D004151 Dipeptides Peptides composed of two amino acid units. Dipeptide
D005260 Female Females

Related Publications

V Umnerová, and M Jarolím, and A Jindra, and M Jáchymová, and J Peleska, and J Savlíková, and P Stolba, and K Horký
Control of essential hypertension with captopril, an angiotensin converting enzyme inhibitor.
May 1981, British journal of clinical pharmacology,
V Umnerová, and M Jarolím, and A Jindra, and M Jáchymová, and J Peleska, and J Savlíková, and P Stolba, and K Horký
Lisinopril: a new angiotensin-converting enzyme inhibitor.
May 1988, Drug intelligence & clinical pharmacy,
V Umnerová, and M Jarolím, and A Jindra, and M Jáchymová, and J Peleska, and J Savlíková, and P Stolba, and K Horký
Lisinopril: a new angiotensin-converting enzyme inhibitor.
January 1989, Pharmacotherapy,
V Umnerová, and M Jarolím, and A Jindra, and M Jáchymová, and J Peleska, and J Savlíková, and P Stolba, and K Horký
Lisinopril: a nonsulfhydryl angiotensin-converting enzyme inhibitor.
September 1988, Clinical pharmacy,
V Umnerová, and M Jarolím, and A Jindra, and M Jáchymová, and J Peleska, and J Savlíková, and P Stolba, and K Horký
Lisinopril, a new angiotensin converting enzyme inhibitor.
May 1992, The American journal of the medical sciences,
V Umnerová, and M Jarolím, and A Jindra, and M Jáchymová, and J Peleska, and J Savlíková, and P Stolba, and K Horký
Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension.
February 1982, British journal of clinical pharmacology,
V Umnerová, and M Jarolím, and A Jindra, and M Jáchymová, and J Peleska, and J Savlíková, and P Stolba, and K Horký
Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension.
March 1987, British medical journal (Clinical research ed.),
V Umnerová, and M Jarolím, and A Jindra, and M Jáchymová, and J Peleska, and J Savlíková, and P Stolba, and K Horký
Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.
November 1979, British medical journal,
V Umnerová, and M Jarolím, and A Jindra, and M Jáchymová, and J Peleska, and J Savlíková, and P Stolba, and K Horký
Angiotensin-converting enzyme inhibitors in essential hypertension.
January 1987, Journal of cardiovascular pharmacology,
V Umnerová, and M Jarolím, and A Jindra, and M Jáchymová, and J Peleska, and J Savlíková, and P Stolba, and K Horký
Effect of the angiotensin-converting enzyme inhibitor perindopril on haemostasis in essential hypertension.
October 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
Copied contents to your clipboard!